Value Investing Scorecard
Merck & Co., Inc. (MRK) stock analysis
Updated daily. This free report scores MRK on business quality, financial strength, valuation, and downside protection so long-term investors can judge whether the stock is worth deeper research.
Business QualityFinancial StrengthValuationMargin Of Safety
Free Screen
Merck & Co., Inc.
MRK
Fails Value Screen
The stock trades above even the bullish-case DCF estimate, so it fails the margin-of-safety test at the current price. Valuation capped at 5 because the current price is above the bullish-case DCF value. Conservative-case spread versus market price is -219.9%.
0/100Fails Value Screen
Dimension Breakdown
Business Quality15 / 20
Financial Strength18 / 25
Management14 / 15
Valuation / Margin of Safety4 / 25
Macro5 / 10
Key Metrics
Revenue Growth (3Y)
9.7%
↑
Gross Margin
74.8%
↑
Debt / EBITDA
1.91x
↑
FCF Margin
19%
↑
Conservative MoS
-219.9%
↓
Red Flags
⚠️
R&D Spend CollapsingMedium
R&D intensity has fallen sharply for a tech or pharma business.
Intrinsic Value Estimates
Current Market Price
$148.78
Conservative Case
$46.51
-219.9% above
Bullish Case
$75.01
-98.4% above
⚠️ Trades 98.3% above Bullish Case — Overvalued by all scenarios
Management Quality
Macro & Sector Context
Share this analysis
See the assumptions, valuation stack, and the rest of the report.
📊
DCF Fair Value — Full model — WACC, terminal value, sensitivity analysis
🎯
Margin of Safety — Exact downside buffer before you overpay
👔
Management Score — CEO tenure, buyback discipline, insider ownership
🌍
Macro Analysis — Rate sensitivity, inflation exposure, sector tailwinds
🚨
Full Red Flags — Complete risk inventory — every flag, uncapped
Shared links are public. Full report unlock happens on the main app with sign-in and credits.
This is an educational research screen, not investment advice.
MRK Full Report—$2.99 for 1 credit | $9.99 for 5 credits
Copied!